Safety and Tolerability of Intrathecal Liposomal Cytarabine during CNS Prophylaxis in Patients with Non Hodgkin Lymphoma and Acute Lymphoblastic Leukemia.
Authors: Annino Luciana , Anaclerico Barbara , Benevolo Giulia , Cascavilla Nicola , Cimminiello Michele , Dell’Olio Matteo , Gagliardi Alfredo , Giordano Giulio , Miraglia Eustachio , Musso Maurizio , Parvis Guido , Piano Silvia , Pilatrino Chiara , Scalone Renato , Venditti Adriano , Venditti Daniela , Vitolo Umberto , Storti Sergio 
Published: November 2019

Abstract
Meningeal recurrence in aggressive NHL and ALL occurs in up to 20% of patients and mostly depends on intensity and efficacy of front-line CNS prophylaxis. Liposomal cytarabine (lip araC) is a sustained release formulation of araC with a homogeneous distribution in the neuraxis and a prolonged half life, maintening cytotoxic concentrations in the CSF for more than 14 days. The present study aims to evaluate the safety and tolerability of lip araC in the CNS prophylaxis of NHL and ALL meningeal recurrences. Forty-four patients aged 16–77 years (median 43,9) have been preventively treated with a total of 159 (range: 1–8) doses of lip araC 50 mg. Diagnosis consisted on 33 NHL: 14 high risk-CNS DLBCL (involvement of testes, paranasal sinuses, hard palate, orbit, paravertebral masses and bone marrow or IPI ≥2 with high level of LDH and ≥1 extranodal site involvement), 7 BL, 2 blastoid mantle cell, 7 lymphoblastic, 1 gastric marginal zone lymphoma, 1 anaplastic, 1 follicular, and 11 ALL: 7 B-ALL, 3 T-ALL, 1 hybrid cells. Five patients (1 DLBCL, 1 BL, 2 T-ALL, 1 B-ALL) received lip araC at their 1st systemic recurrence; of them, the DLBCL did not receive previous prophylaxis, instead of the T-ALLs had standard treatment with IT MTX; BL and B-ALL received not specified prophylactic therapy. All patients were treated according to the standard protocols in use for their disease; in particularly, NHL received RCHOP-like treatments, a part of 5 BL (RCODOX-M/R-IVAC-like therapy) and 5 lymphoblastic (hyperC VAD/HD MTX/araC); ALL patients received standard treatments according with GIMEMA, NILG and BMF protocols. Five patients (2 DLBCL, 2 BL and 1 B-ALL) underwent autotransplantation. Four patients received IT or HD systemic MTX during treatment with lip araC. Seven patients received RT, as a part of prophylaxis program. All patients received lip araC 50 mg every 2, 3, 4 or 8 weeks, excepted 2 receiving 30 mg. All patients had corticosteroids for prevention of chemical aracnoiditis. A part of an episode of G2 headache and 18 cases of G1 headache, 8 episodes of G1 nausea/vomiting and 2 cases of localized or diffuse bone pain, no severe toxicity has been noted. So far, after a medium observation period of 9 months (range 1–26) only 1 patient, affected by mantle cell lymphoma, showed CNS recurrence 10 months after diagnosis while in systemic relapse and died. None of the patients developed neurological symptoms or unexpected long term neurological side effects. IT lip araC therapy with concomitant corticosteroids appears to be feasible and well tolerated in the prophylactic setting. Because of only few patients received CNS-directed concomitant therapy, lip araC appears effective towards CNS recurrence in the high risk NHL and ALL. More randomized studies are warranted.